A Multicenter Randomized Comparison of 22G FNB Needle vs. 19G FNB Needle in Ultrasound Endoscopy-Guided Tissue Collection for Cancer Gene Panel Testing in Unresectable Advanced or Recurrent Pancreatic Cancer (G-Precision trial)

未提供0 个研究点目标入组 100 人开始时间: 2024年3月15日最近更新: 2024年5月29日

适应症

试验速览

暂无简介。

•Patients with unresectable advanced or recurrent pancreatic cancer diagnosed by pathological or imaging findings
•Patients who are scheduled to undergo EUS-TA
•Patients who are scheduled to undergo CGP examination using EUS-TA specimen at the time of completion or expected completion of standard treatment.
•18 years of age or older
•Patients who are expected to survive more than 3 months.
•Patients who have been fully informed about the study, understand it, and give written consent of their own free will.

•Patients with resectable pancreatic cancer or borderline resectable pancreatic cancer who are scheduled for surgery in the future
•Patients with performance status 3-4
•Patients who have difficulty in receiving anti-tumor therapy
•Patients with bleeding tendency (platelets <50,000/mm3, PT <70%) (however, patients who recover with blood transfusion or vitamin K administration may be enrolled)
•Patients at high risk of thromboembolism due to withdrawal of antithrombotic drugs and for whom withdrawal or replacement of antithrombotic drugs based on the "Guidelines for Gastrointestinal Endoscopy for Patients Taking Antithrombotic Drugs" is not possible.
•Patients with heart failure (NYHA classification III-IV) or respiratory failure (PaO2 < 60 Torr)
•Patients who are pregnant or may become pregnant
•Other cases that the principal investigator determines to be inappropriate as a research subject.

The success rate of CGP testing

未报告次要终点

发起方

未提供